Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens

Irene Olivera; Iñaki Etxeberria; Elixabet Bolaños; María Gato-Cañas; Ignacio Melero

doi:10.1158/1078-0432.CCR-19-3813

Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens

Clin Cancer Res. 2020 Mar 15;26(6):1203-1204. doi: 10.1158/1078-0432.CCR-19-3813. Epub 2020 Jan 30.

Authors

Irene Olivera^{1

2}, Iñaki Etxeberria^{1

2

3}, Elixabet Bolaños^{1

2

3}, María Gato-Cañas^{1

2

3}, Ignacio Melero^{4

2

3

5}

Affiliations

¹ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
² Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
³ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
⁴ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain. imelero@unav.es.
⁵ Department of Immunology, Clinical Universidad de Navarra, Pamplona, Spain.

PMID: 32001482
DOI: 10.1158/1078-0432.CCR-19-3813

Abstract

T-cell recognizable p53 hotspot mutations offer opportunities for immunotherapy and immune monitoring. Recognition of p53 mutations by peripheral blood CD8 and CD4 T lymphocytes has been revealed.See related article by Malekzadeh et al., p. 1267.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antigens, Neoplasm* / genetics
CD4-Positive T-Lymphocytes / metabolism
Humans
Immunotherapy
Receptors, Antigen, T-Cell / genetics
Receptors, Antigen, T-Cell / metabolism
Tumor Suppressor Protein p53* / genetics

Substances

Antigens, Neoplasm
Receptors, Antigen, T-Cell
Tumor Suppressor Protein p53